Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary by Heidbuchel, Hein et al.
Updated European Heart Rhythm Association
practical guide on the use of non-vitamin-K
antagonist anticoagulants in patients with
non-valvular atrial fibrillation: Executive
summary
Hein Heidbuchel1*, Peter Verhamme2, Marco Alings3, Matthias Antz4,
Hans-Christoph Diener5, Werner Hacke6, Jonas Oldgren7, Peter Sinnaeve2,
A. John Camm8, and Paulus Kirchhof9,10
Advisors: Azhar Ahmad, M.D. (Boehringer-Ingelheim Pharma), Jutta Heinrich-Nols,
M.D. (Boehringer-Ingelheim Pharma), Susanne Hess, M.D. (Bayer Healthcare
Pharmaceuticals), Markus Müller, M.D., Ph.D. (Pfizer Pharma), Felix Münzel, Ph.D.
(Daiichi-Sankyo Europe), Markus Schwertfeger, M.D. (Daiichi-Sankyo Europe),
Martin van Eickels, M.D. (Bayer Healthcare Pharmaceuticals), and
Isabelle Richard-Lordereau, M.D. (Bristol-Myers-Squibb/Pfizer)
Document reviewers: Gregory Lip, (Reviewer Coordinator; UK), Chern-En Chiang,
(Taiwan), Jonathan Piccini, (USA), Tatjana Potpara, (Serbia), Laurent Fauchier,
(France), Deirdre Lane, (UK), Alvaro Avezum, (Brazil), Torben Bjerregaard Larsen,
(Denmark), Guiseppe Boriani, (Italy), Vanessa Roldan-Schilling, (Spain), and
Bulent Gorenek, (Turkey)
1Hasselt University and Heart Center, Stadsomvaart 11, Hasselt 3500, Belgium; 2Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; 3Department of
Cardiology, Amphia Ziekenhuis, Breda, The Netherlands; 4Department of Cardiology, Klinikum Oldenburg, Oldenburg, Germany; 5Department of Neurology, University Hospital
Essen, University Duisburg-Essen, Essen, Germany; 6Department of Neurology, Ruprecht Karls Universität, Heidelberg, Germany; 7Department of Medical Sciences, Uppsala Clinical
Research Center, Uppsala University, Uppsala, Sweden; 8Clinical Cardiology, St George’s University, London, UK; 9University of Birmingham Centre for Cardiovascular Sciences,
Birmingham, UK; and 10Department of Cardiology and Angiology, University of Münster, Münster, Germany
In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in
patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof
P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with
non-valvular atrial fibrillation. Europace 2013;15:625–651; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve
P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive
summary. Eur Heart J 2013;34:2094–2106). The document received widespread interest, not only from cardiologists but also from neurolo-
gists, geriatricians, and general practitioners, as became evident from the distribution of .350 000 copies of its pocket version (the EHRA Key
Message Booklet) world-wide. Since 2013, numerous new studies have appeared on different aspects of NOAC therapy in AF patients. There-
fore, EHRA updated the Practical Guide, including new information but also providing balanced guiding in the many areas where prospective
* Corresponding author. Tel: +32 11 30 95 75, fax: +32 11 30 78 39, Email: hein.heidbuchel@jessazh.be; heinheid@gmail.com
This is an abridged version of an article published in Europace: Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;
17:1467–1507.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2016. For permissions please email: journals.permissions@oup.com.
doi:10.1093/eurheartj/ehw058
Online publish-ahead-of-print 9 June 2016









alavasi user on 09 N
ovem
ber 2020
data are still lacking. The outline of the original guide that addressed 15 clinical scenarios has been preserved, but all chapters have been
rewritten. Main changes in the Update comprise a discussion on the definition of ‘non-valvular AF’ and eligibility for NOAC therapy, inclusion
of finalized information on the recently approved edoxaban, tailored dosing information dependent on concomitant drugs, and/or clinical char-
acteristics, an expanded chapter on neurologic scenarios (ischaemic stroke or intracranial haemorrhage under NOAC), an updated anticoa-
gulation card and more specifics on start-up and follow-up issues. There are also many new flow charts, like on appropriate switching between
anticoagulants (VKA to NOAC or vice versa), default scenarios for acute management of coronary interventions, step-down schemes for long-
term combined antiplatelet-anticoagulant management in coronary heart disease, management of bleeding, and cardioversion under NOAC
therapy. The Updated Guide is available in full in EP Europace (Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J,
Sinnaeve P, Camm AJ, Kirchhof P, Advisors. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antag-
onist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–1507), while additional resources can be found at
the related ESC/EHRA website (www.NOACforAF.eu).
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Introduction
The proper use of non-vitamin K antagonist (VKA) oral anticoagu-
lants (NOACs) for thromboembolic prevention in patients with
non-valvular atrial fibrillation (AF) requires different approaches
in many daily care settings compared with VKAs. Guidelines4 – 6
mainly discuss the indications for anticoagulation in general
(e.g. based on the CHA2DS2-VASc score; NOAC vs. VKA). This
Practical Guide supplements the Guidelines, providing guidance
on how to use NOACs in specific clinical situations. The main
changes from the original European Heart Rhythm Association
(EHRA) Practical Guide that was published in 20131,2 are sum-
marized in this Executive Summary. The full text of the Update
is published in EP Europace.3 The Update will also be presented
in an new version of the slide kit (downloadable for free by
EHRA members) and a Key Message booklet, which can be
obtained through EHRA and ESC. Stay tuned to the www.
NOACforAF.eu Web site for up-to-date information. You can
also provide your feedback via that Web site.
Definition of ‘non-valvular atrial
fibrillation’ and eligibility for
NOACs
Valvular AF refers to AF that occurs in the presence of mechanical
prosthetic heart valves or of moderate-to-severe mitral stenosis
(usually of rheumatic origin). Both types of patients were ex-
cluded from all NOAC trials and are not eligible for NOAC ther-
apy. Atrial fibrillation patients often have other valvular
abnormalities many of which were included in the NOAC trials.
They were shown to be suitable NOAC candidates based on
the consistent beneficial findings in these subgroups (with the ex-
ception of higher bleeding rates with rivaroxaban compared with
VKA in patients with valvular disease).7 – 9 Table 1 summarizes the
eligibility recommendations for NOAC therapy for other patient
subgroups, acknowledging that limited data are available for some
groups.10 The full Guide describes the rationale for this eligibility
guidance.
Expanded data on all four
NOAC drugs
Although already provisionally present in the original Practical
Guide, all the latest information on edoxaban, the most recently ap-
proved NOAC, has been included in the Update. The standard dose
of edoxaban is 60 mg once daily (OD), with prespecified dose re-
ductions in patients with a reduced kidney function (CrCl estimated
by the Cockcroft-Gault formula of ≤49 mL/min), the concomitant
use of certain drugs (e.g. dronedarone), and in patients weighing
≤60 kg. The table from the original Guide that highlights all known
drug–drug interactions and clinical factors that impact NOAC plas-
ma levels has been updated and re-organized (Table 2). The table
aims to provide physicians with a clear rationale to optimize the
NOAC dose for particular patients, preventing both under- and
overtreatment. The table uses a color-coded scheme to indicate si-
tuations with a contraindication for concomitant NOAC use (‘red’),
necessity to reduce its dose (‘orange’), or consideration of dose re-
duction in the presence of other ‘yellow’ factors. Some cells with
missing pharmacokinetic interaction data have now been filled in (al-
though some retain the ‘no data yet’ label . . .), drugs are classified
according to therapeutic area for easier reference, and there has
been a separate color coding for interactions that lead to reduced
NOAC plasma levels (vs. the more usual scenario of increased
plasma levels).
Also the impact of the different NOACs on standard and specific
coagulation assays has been revised and made more specific where
possible. Information on the activated clotting time and quantitative
trough plasma levels for all drugs have been added.
The addition of edoxaban also called for updates of the recom-
mendations concerning switching anticoagulants (Figure 1). When
switching from VKA therapy to NOAC (upper panel), the proposed
scheme in the Practical Guide unifies instructions from Summary of
Product Characteristics (SmPC) for the different NOACs, that state
that NOAC can be started when international normalized ratio
(INR) is ≤3 for rivaroxaban, ≤2.5 for edoxaban, and ≤2 for apix-
aban and dabigatran. The Guide advises uniformly that if the INR is
2.0–2.5, the NOAC can be started immediately or the next day. For
INR .2.5, the actual INR value and the half-life of the VKA need to
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be taken into account to estimate the time when the INR value will
likely drop to within this threshold range. At that time, a new INR
measurement can be scheduled. Inadequate transitioning from
NOAC to VKA has been shown to be associated with increased
stroke rates.11 – 13 Therefore, a more rigorous switching scheme
has been proposed (Figure 1, lower panel), taking into account
that NOACs (especially the FXa inhibitors) may have an effect on
the INR, influencing the measurement while on combined treat-
ment during the overlap phase. INR should be measured just before
the next intake of the NOAC during concomitant administration,
and be retested 24 h after the last dose of the NOAC (i.e. sole
VKA therapy) to assure adequate anticoagulation. It is also recom-
mended to closely monitor INR within the first month until stable
therapeutic values have been attained. At the end of the
ENGAGE-AF trial, patients on edoxaban transitioning to VKA re-
ceived up to 14 days of a half dose of the NOAC until INR was with-
in range, in combination with the above intensive INR testing
strategy.14 Whether the half-dose bridging regimen also applies to
other NOACs is unknown.
Peri-procedural management
of NOAC-treated patients
The table on the timing of intake of last NOAC before elective sur-
gery (Table 3) has been simplified since edoxaban follows the same
regime as the other FXa inhibitors. The table stresses that pre-
operative bridging with low-molecular-weight heparins (LMWH)
is inappropriate in the context of NOAC therapy, since it will
only increase perioperative bleeding risk.15 The time of last intake
depends on the type of intervention, distinguishing interventions
that do not necessarily require discontinuation of anticoagulation
and can be done at trough level, those with minor bleeding risk
(i.e. infrequent or with low clinical impact) usually requiring last in-
take ≥24 h before (if normal renal function; longer if reduced CrCl),
and those with major bleeding risk (i.e. frequent and/or with high im-
pact) requiring a default of ≥48 h cessation.
If emergency surgery is required that cannot be delayed, specific
or aspecific reversal of the anticoagulant may be considered by the
agents mentioned below under ‘Management of bleeding’.
EHRA/HRS/APHRS recently published an extensive consensus
document on antithrombotic management in patients undergoing
electrophysiological procedures.16 The Updated Practical Guide is
in line with those recommendations. In patients undergoing device
implantation, there is consensus about lower thromboembolic and
bleeding rates with uninterrupted VKA, at least in patients with an
increased embolic risk.17 For NOAC-treated patients, we do not
see a reason to deviate from the overall scheme with timed cessa-
tion before intervention, without bridging (Table 3). Smaller studies
did not show a benefit of uninterrupted NOAC (and even a trend
for more bleeding).18,19
Best management of anticoagulation around pulmonary vein iso-
lation (PVI) remains elusive given the heterogeneity of studies per-
formed. Although associated with a risk for frequent or major
bleeding, PVI is also associated with a high thromboembolic risk.
There is international consensus that in VKA-treated patients PVI
should be performed without VKA interruption.4,20,21 Whether
such an approach is safe in patients on NOAC therapy is less clear.
Non-vitamin-K antagonist oral anticoagulants have the advantage of
predictable waning/onset of their anticoagulant effect, without need
for bridging with LMWH which was the prime reason for the peri-
procedural bleedings as seen in bridged VKA patients. A first rando-
mized trial, Venture-AF (with rivaroxaban, of which the last dose
was presumably given 12 h before the procedure in most patients;
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Valvular indications and contra-indications for NOAC therapy in atrial fibrillation patients
Eligible Contra-indicated
Mechanical prosthetic valve 3
Moderate-to-severe mitral stenosis (usually
of rheumatic origin)
3
Mild-to-moderate other native valvular disease 3
Severe aortic stenosis 3
Limited data
Most will undergo intervention
Bioprosthetic valvea 3
(except for the first 3 months post-operatively)
Mitral valve repaira 3
(except for the first 3–6 months post-operatively)
PTAV and TAVI 3
(but no prospective data; may require combination with single or double
antiplatelets: consider bleeding risk)10
Hypertrophic cardiomyopathy 3
(but no prospective data)
PTAV, percutaneous transluminal aortic valvuloplasty; TAVI, transcatheter aortic valve implantation.
aAmerican guidelines do not recommend NOAC in patients with biological heart valves or after valve repair.12
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Table 2 Effect on NOAC plasma levels (‘area under the curve, AUC’) from drug–drug interactions and clinical factors,
and recommendations towards NOAC dose adaptation
 Via Dabigatran Apixaban Edoxaban Rivaroxaban
Antiarrhythmic drugs: 
Amiodarone moderate P-gp 
competition
+12-60% No PK dataa +40% Minor effecta (use 









No effect +40% No data yet Minor effect (use 
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data: caution 
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No data yet Up to +153%
Continued




















































H2B; PPI; Al-Mg-hydroxide GI absorption Minus 12-
30%













minus 35% Up to minus
50%
Other factors:
Age  80 years Increased 
plasma level 
b d
Age 75 years Increased 
plasma level
d 
Weight  60 kg Increased 
plasma level
b 
Renal function Increased 
plasma level
See specific dose instructions according to renal function
Other increased bleeding 
risk
Pharmacodynamic interactions (antiplatelet drugs; NSAID; systemic 
steroid therapy; other anticoagulants); history of GI bleeding; recent 





 Via Dabigatran Apixaban Edoxaban Rivaroxaban
Red: contra-indicated/not recommended. Orange: reduce dose (from 150 mg BID to 110 mg BID for dabigatran; from 20 to 15 mg OD for rivaroxaban; from 5 mg BID to 2.5 mg
BID for apixaban). Yellow: consider dose reduction if two or more ‘yellow’ factors are present.
Hatching: no clinical or PK data available.
BCRP, breast cancer resistance protein; NSAID, non-steroidal anti-inflammatory drugs; H2B, H2-blockers; PPI, proton pump inhibitors; P-gp, P-glycoprotein; GI, gastro-intestinal.
aBased on in vitro investigations, comparing the IC50 for P-gp inhibition to maximal plasma levels at therapeutic dose, and/or on interaction analysis of efficacy and safety endpoints in
the phase-3 clinical trials. No direct PK interaction data available.
bSome interactions lead to reduced NOAC plasma levels in contrast to most interactions that lead to increased NOAC plasma levels. This may also constitute a contraindication for
simultaneous use, and such cases are colored brown. The label for edoxaban mentions that co-administration is possible in these cases, despite a decreased plasma level, which are
deemed not clinically relevant (blue). Since not tested prospectively, however, such concomitant use should be used with caution, and avoided when possible.
cThe SmPC specifies dose reduction from 5 mg BID to 2.5 mg BID if two of three criteria are fulfilled: age ≥80 years, weight ≤60 kg, and serum creatinine ≥1.5 mg/dL.
dAge had no significant effect after adjusting for weight and renal function.
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no exact data reported), showed similar bleeding and ischaemic
event rates, although in a rather small population leading to an
underpowered trial.22 Therefore, while awaiting data from other
ongoing prospective trials, we recommend an institutional protocol
for NOAC patients undergoing AF ablation. This may consist of
changing patients to uninterrupted VKA, of uninterrupted NOAC
therapy, or of well-planned cessation of NOAC. Meta-analysis
data indicate that a last intake of NOAC 24 h before the procedure
Figure 1 Switching between vitamin-K antagonists (VKA) and non-VKA oral anticoagulants (NOACs) and vice versa.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Last intake of drug before elective surgical intervention
Dabigatran Apixaban–Edoxaban–Rivaroxaban
No important bleeding risk and/or adequate local haemostasis possible: perform at
trough level (i.e. ≥12 or 24 h after last intake)
Low risk High risk Low risk High risk
CrCl ≥80 mL/min ≥24 h ≥48 h ≥24 h ≥48 h
CrCl 50–80 mL/min ≥36 h ≥72 h ≥24 h ≥48 h
CrCl 30–50 mL/mina ≥48 h ≥96 h ≥24 h ≥48 h
CrCl 15–30 mL/mina Not indicated Not indicated ≥36 h ≥48 h
CrCl ,15 mL/min No official indication for use
There is no need for pre-operative bridging with LMWH/UFH
Bold values deviate from the common stopping rule of ≥24 h low risk, ≥48 h high risk.
Low risk: with a low frequency of bleeding and/or minor impact of a bleeding; high risk with a high frequency of bleeding and/or important clinical impact.
CrCl, creatinine clearance.
aMany of these patients may be on the lower dose of dabigatran (i.e. 110 mg BID) or apixaban (i.e. 2.5 mg BID), or have to be on the lower dose of rivaroxaban (i.e. 15 mg OD) or
edoxaban (i.e. 30 mg OD).
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is a viable ‘default’ strategy. Continued intake until the evening be-
fore the procedure or even the morning of the procedure seems
to be safe in experienced centres. A number of factors should be
considered for the timing of last intake, like kidney function, CHA2-
DS2-VASc score of the patient, experience of the operator, type and
extent of additional ablation beyond PVI, and the presence of peri-
procedural imaging to guide transseptal puncture. When NOAC is
last taken ≥36 h before the intervention, a transoesophageal
echocardiography (TOE) should be considered before ablation.
The same applies if adherence to correct NOAC intake in the weeks
before ablation is doubtful.
Management of bleeding
Recent progress in the development of specific reversal agents is
summarized in the Updated Guide. A specific reversal agent for da-
bigatran (idarucizumab, a humanized antibody fragment that specif-
ically binds dabigatran)23 is close to approval by EMA and FDA. The
REVERSE-AD trial showed a nearly complete reversal of the anti-
coagulant effects of dabigatran by idarucizumab within minutes.24
Similar agents for FXa inhibitors are under development, such as
andexanet alfa (a recombinant human FXa analogue that competes
for the FXa inhibitors with FXa) and aripazine, a small synthetic mol-
ecule that seems to have more generalized antagonistic effects.25,26
A graded approach to bleeding is presented in Figure 2. When idar-
ucizumab would not be readily available during a major bleeding
complication under dabigatran, or in case bleeding occurs in a pa-
tient treated with any of the FXa inhibitors, one can resort to
nonspecific reversal strategies: many animal and healthy volunteer stud-
ies have confirmed the effects of prothrombin complex concentrate
(PCC) or activated prothrombin complex concentrates (aPCC),27,28
but newer research has indicated that the dose of PCC needed for
full reversal is higher than stated in the original Practical Guide, and
thus has been updated accordingly (50 U/kg vs. 25 U/kg).27–29 The ef-
ficacy of PCC or aPCC in patients who are actively bleeding has not
been firmly established (i.e. that they reduce blood loss and improve
outcome),30 and one has to balance the potential pro-thrombotic ef-
fects against the potential anticoagulant benefits.31,32
Cardioversion
A new flowchart has been added to depict different clinical scen-
arios related to electrical cardioversion (Figure 3). In patients on
long-term NOAC therapy (i.e. ≥3 weeks), subgroup analyses
from the different trials have shown that electrical cardioversion
had a similar (and very low) thromboembolic risk as under war-
farin.33– 35 The recently published X-VeRT trial confirmed the low
peri-cardioversion stroke risk in patients treated with rivaroxaban
compared with warfarin in a prospective, controlled design, al-
though with insufficient patient numbers to demonstrate statistically
sound non-inferiority.36 As there is no coagulation assay available
for any NOAC that provides information on effective anticoagula-
tion over the past 3 weeks, it is mandatory to explicitly ask the pa-
tient about adherence over the last weeks and to document the
answer in their file. If in doubt about adherence, a TOE should be
performed prior to cardioversion.
Figure 2 Management of bleeding in patients taking NOACs. Possible therapeutic measures in case of minor or severe bleeding in patients on
NOAC therapy. Based on van Ryn et al.34
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In patients with new-onset AF present for .48 h in whom
early cardioversion is preferred without ≥3 weeks pre-treatment
with NOACs, a strategy with at least a single NOAC dose ≥4 h
before cardioversion is safe and effective, provided that a TOE is
performed prior to cardioversion. This strategy has been evaluated
in X-VeRT36 and is under evaluation in ongoing trials with other
NOACs.
Whether intake of at least 1 pill of NOAC is a feasible strategy in
patients with AF of ≤48 h duration, who are currently often cardi-
overted after a single dose of LMWH or start of unfractionated hep-
arin (with continuation of anticoagulation for ≥4 weeks later on)
needs further study. Some of these patients are being included in on-
going trials. In the absence of such data, we recommend adherence
to current institutional practice with/without heparin/LMWH and
with/without TOE in these patients.
Atrial fibrillation patients with
coronary artery disease and in need
of (concomitant) antiplatelet
therapy
One of the most complex clinical settings comprises the antithrom-
botic management of AF patients with an acute coronary syndrome
(ACS), in need of an elective coronary intervention, or with chronic
vascular disease with an indication for single or dual antiplatelet
therapy. The number of scenarios, the number of available drugs,
and their combinations are so extensive that there is only a paucity
of specific data that can guide the clinician in an individual setting.
The Updated guide gives a background overview of ‘key scientific’
data in this field, before providing guidance on acute and long-term
clinical scenarios. We recognize that institutions and physicians have
their own strategies: in the light of all the knowledge gaps, they
should not consider our guidance as a rule written in stone, but ra-
ther as a foundation (‘default strategy’) to base their own approach.
For each scenario, we have highlighted the evidence gaps, and pro-
vided patient factors that have to be weighed in the balance to shift
away from the default scenario into different directions, in line with
other ESC consensus statements.37 These default scenarios are
summarized in two completely new flowcharts, one on ‘acute man-
agement of elective revascularization or ACS in AF patients treated
with NOAC’ (Figure 4) and another on ‘default scenarios and
criteria for adaptation for long-term treatment of patients on
NOAC therapy after revascularization or ACS’ (Figure 5).
The acute scenario (Figure 4) constitutes coronary interventions
in AF patients already on NOACs. Whereas guidelines recommend
to maintain VKA patients uninterrupted on their treatment, both
during elective or urgent percutaneous coronary intervention
(PCI), NOACs should preferably be temporarily discontinued
for elective interventions and upon presentation with ACS. This al-
lows safe initiation of antiplatelet therapy and standard local
Figure 3 Cardioversion work-flow in AF patients treated with NOACs, depending on the duration of the arrhythmia and prior anticoagulation.
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anticoagulation practices peri-procedurally. In stabilized patients
(i.e. no recurrent ischaemia or need for other invasive treatment),
anticoagulation can be restarted after parenteral anticoagulation is
stopped. It is reasonable to restart the NOAC that the patient
was taking before the ACS or elective procedure. There are no
data to recommend switching to VKA (which may even be asso-
ciated with higher bleeding and thromboembolic risks, especially
in VKA-naı̈ve patients in whom the correct VKA dose is unknown),
or to one particular NOAC. The same applies for AF patients after
coronary bypass grafting. Whereas it has been shown that the lower
dose of dabigatran (110 mg BID) is non-inferior to VKA for stroke
prevention but has a lower risk of major bleeding compared with
VKA and dabigatran 150 mg BID, also in patients receiving antiplate-
let treatment, this dose can be considered during the combination
phase.38 The benefits in stroke prevention in patients with a normal
renal function is uncertain in patients with the lower dosages of
the other NOACs, and such lower-dose choice can therefore not
be recommended for those other agents.
Concerning long-term management (Figure 5), patients after re-
vascularization and/or ACS need to be discharged with a prespecified
downgrade schedule of antithrombotic agents (i.e. from triple to
double therapy, and from double therapy to anticoagulation in
monotherapy) to reduce the risk of bleeding while protecting
against coronary events. After elective PCI or ACS, we propose a
default time of triple therapy of 1 month and 6 months for a bare
metal stent or newer DES stent, respectively, thereafter stepping
down to double therapy (with OAC and either aspirin or clopido-
grel) until 1 year. Factors that weigh in to lengthen or shorten the
periods on triple and double therapy are indicated in the flowchart.
In a small subset of patients with a low stroke risk (CHA2DS2-VASc
of 1 in males or 2 in females, i.e. only CAD) and elevated bleeding
risk, one could opt to treat with only dual antiplatelet therapy, with-
out anticoagulants, although in ACTIVE-W there were numerically
more myocardial infarctions (MIs) with aspirin plus clopidogrel com-
pared with warfarin.39
For all coronary artery disease (CAD) patients with AF, the
default is to step down to anticoagulation in monotherapy after
1 year, except for those with a very high risk for coronary events
and an acceptably low bleeding risk. There is no indication that
the advantages of NOACs (in monotherapy) over VKAs are not
preserved in CAD patients with AF. Lacking direct comparative
data, there is also no strong argument for preferring one NOAC
over others in this setting.
Neurological situations
In analogy with the different clinical circumstances with CAD, both
acute and chronic neurological situations are considered in the Prac-
tical Guide. Acute intracerebral haemorrhage (ICH) under NOAC
therapy constitutes a particular subform of acute bleeding. Until the
Figure 4 Acute management of revascularization or acute coronary syndrome in AF patients treated with NOACs. See text for further
discussion.
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new antidotes for NOACs become available, nonspecific procoagu-
lants such as PCC or aPCC can be considered, although their impact
on prognosis is unknown. Patients presenting with acute ischaemic
stroke under (N)OAC therapy present an even greater clinical con-
undrum. Until there are reliable and sensitive rapid (point-of-care)
tests for the individual NOAC, we would discourage the use of
thrombolytics in situations with uncertainty about the anticoagula-
tion status or when NOACs have been administered within the last
24(248) h. Mechanical recanalization of occluded vessels with stent
retrievers may be considered as an alternative treatment option,
although no prospectively collected data exist in patients under
NOAC therapy.
Although a history of a spontaneous ICH constitutes a contraindi-
cation against anticoagulation, patients with a prior ICH have higher is-
chaemic stroke and mortality rates, partly due to the cessation
of anticoagulation after the ICH.40,41 The Guide summarizes consid-
erations related to different types of intracranial bleeding about the
potential to restart NOAC therapy. It also provides a flowchart on
the timing for restart of anticoagulation after an ischaemic stroke, de-
pending on its size and/or additional imaging (Figure 6). This scheme
currently undergoes prospective validation in ongoing clinical trials.
Patients with AF and known carotid athorothrombosis with
mild-to-moderate asymptomatic stenosis can be treated with
NOACs only, without the need for additional antiplatelet therapy,
in analogy with stable CAD patients as described above. Patients
with AF and symptomatic high-degree stenosis of the internal ca-
rotid artery should be operated and not stented. This avoids pro-
longed triple therapy with high risk of major bleeding in stented
patients. In patients undergoing endarterectomy, addition of aspirin
is recommended immediately prior to and for 10 days after
surgery.42
Other practical considerations
The need for proper patient education and a well-structured follow-
up have been reiterated from the original Practical Guide. Before
prescribing anticoagulation and considering an NOAC to a patient
with AF, kidney function (expressed by a Cockcroft-Gault estimate
of glomerular filtration rate, GFR) is required, since NOACs have
exclusions and dose recommendations based on GFR. The Guide
lists online free GFR and frailty calculators that may assist in
decision-making. In the absence of clinical data or experience,
NOAC therapy should be avoided in AF patients on haemodialysis
or pre-terminal chronic kidney disease (CrCl ≤15 mL/min), al-
though even the benefit of VKAs in such patients is not unequivocal-
ly proven.
Figure 5 Default scenarios and criteria for adaptation for long-term treatment of patients on NOAC therapy after revascularization or acute
coronary syndrome. There are innumerable possible variations on this global theme, as discussed in the text. Patient characteristics and institu-
tional practices should be taken into account to individualize the approach. This figure wants to create a ‘backbone’ as guidance for such tailored
approaches. A: aspirin 75–100 mg OD; C: clopidogrel 75 mg OD.
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The uniform EHRA NOAC Anticoagulation Card, proposed in
2013 and available for download in 16 languages, has been slightly
modified: there is a dedicated box to state the rationale and planned
cessation date of any concomitant antiplatelet therapy; the card ac-
knowledges the participation of pharmacists during follow-up; and
the schedule for laboratory checks (especially kidney function)
has been slightly modified. A simple ‘rule’ is to specify a recheck
interval in ‘number of months ¼ CrCl/10’. The card and text em-
phasize the need for education, both of the patient and other care-
givers in order to improve adherence. Plasma level monitoring
cannot be considered as a tool for adherence monitoring. Attention
for adherence during regular follow-up visits, technological aids (like
smartphone reminders; electronic pill boxes, and a centralized phar-
macy dispensing database) may be other tools in a system-wide ap-
proach to improve adherence. The Guide calls for prospective,
methodologically sound studies on NOAC adherence, including
comparing once and twice daily NOACs since the pharma-
codynamic and clinical impact of suboptimal adherence may be
different.43
Conclusions
New tools create new responsibilities. Non-vitamin-K antagonist
oral anticoagulants have been shown to be an attractive alternative
for VKA therapy in AF patients, offering net clinical benefit in a wide
array of patients. Physicians should make themselves feel confident
on using NOAC therapy in clinical practice, and recognize limita-
tions in current knowledge about these drugs. We hope that the
Updated Practical Guide is a valuable resource in that regard.
Acknowledgements
EHRA Scientific Documents Committee: Gregory Y.H. Lip (EHRA
Scientific Documents Committee Chair), Bulent Gorenek (EHRA
Scientific Documents Committee Co-Chair), Christian Sticherling,
Laurent Fauchier, Hein Heidbuchel, Angel Moya Mitjans, Mark
A. Vos, Michele Brignole, Gheorghe-Andrei Dan, Michele Gulizia,
Francisco Marin, Giuseppe Boriani, Deirdre Lane, and Irene
Savelieva.
Funding
This article and derived educational materials (slide set, web site, book-
let, and NOAC card) were produced by and under the sole responsibil-
ity of EHRA, the European Heart Rhythm Association, and supported by
Bayer Pharma AG, Boehringer-Ingelheim, Bristol-Myers-Squibb and Pfi-
zer Alliance, and Daiichi-Sankyo Europe GmbH in the form of an Unre-
stricted Educational Grant. The EHRA writing committee collaborated
with medical advisors from the different companies to assure data ac-
curacy and completeness.
Figure 6 Flowchart for the initiation or re-initiation of anticoagulation after transient ischaemic attack (TIA)/stroke or intracerebral
haemorrhage.









alavasi user on 09 N
ovem
ber 2020
Conflict of interest: H.H. is coordinating clinical investigator for the
Biotronik-sponsored EuroEco study on health-economics of remote
device monitoring. H.H. is a member of the scientific advisory board
of Boehringer-Ingelheim, Bayer, BMS-Pfizer, Daiichi-Sankyo, and
Sanofi-Aventis, received lecturing fees from these same companies
and from Merck, Cardiome, Biotronik, St Jude Medical, and received
unconditional research grants through the University of Leuven from
St Jude Medical, Medtronic, Biotronik, and Boston Scientific Inc.
P.V. has received research funding through the University of Leuven
from Boehringer-Ingelheim, Bayer HealthCare, Daiichi-Sankyo, and
ThromboGenics. P.V. has received speaker honoraria from Boehringer-
Ingelheim, Bayer Healthcare, Daiichi-Sankyo, Pfizer and Sanofi-Aventis.
M.A. has received advisory board fees from Bayer, Boehringer-
Ingelheim, Bristol-Meyer-Squib, Pfizer, and Daiichi-Sankyo, fees for de-
velopment of educational presentations from Boehringer-Ingelheim and
travel support by St Jude Medical.
M.A. has received consulting fees and speaker honoraria from
Biosense Webster, Bayer HealthCare, Boehringer-Ingelheim, Sanofi-
Aventis, Bristol-Myers-Squibb, Daichii-Sankyo, Pfizer, as well as speaker
honoraria from Boston Scientific and Pioneer Medical Devices.
H.C.D. received honoraria for participation in clinical trials, contribu-
tion to advisory boards or oral presentations from: Abbott, Allergan,
AstraZeneca, Bayer Vital, BMS, Boehringer-Ingelheim, CoAxia, Corim-
mun, Covidien, Daiichi-Sankyo, D-Pharm, Fresenius, GlaxoSmithKline,
Janssen-Cilag, Johnson & Johnson, Knoll, Lilly, MSD, Medtronic, Mind-
Frame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion,
Parke-Davis, Pfizer, Sanofi-Aventis, Schering-Plough, Servier, Solvay,
St Jude, Syngis, Talecris, Thrombogenics, WebMD Global, Wyeth and
Yamanouchi. Financial support for research projects was provided by
AstraZeneca, GSK, Boehringer-Ingelheim, Lundbeck, Novartis, Janssen-
Cilag, Sanofi-Aventis, Syngis, and Talecris. Within the past year HCD
served as editor of Aktuelle Neurologie, Arzneimittelthera-pie,
Kopfschmerznews, Stroke News and the Treatment Guidelines of the
German Neurological Society, as co-editor of Cephalalgia and on the
editorial board of Lancet Neurology, Stroke, European Neurology,
and Cerebrovascular Disorders. The Department of Neurology at the
University Duisburg-Essen received research grants from the German
Research Council (DFG), German Ministry of Education and Research
(BMBF), European Union, NIH, Bertelsmann Foundation, and Heinz-
Nixdorf Foundation. HCD has no ownership interest and does not
own stocks of any pharmaceutical company.
W.H. received grants for clinical research from Boehringer-Ingelheim
Pharmaceuticals.
J.O. received institutional research grant from Boehringer-Ingelheim
and has received consulting and speaker fees from Bayer, Boehringer-
Ingelheim, Bristol-Myers-Squibb, and Pfizer.
P.S. has received research funding through the University of Leuven
from AstraZeneca and GSK. P.S. has received speaker and/or consulting
honoraria from Boehringer-Ingelheim, Bayer Healthcare, Daiichi-
Sankyo, Pfizer, Sanofi-Aventis, Bristol-Meyer-Squib, and Abbott J.C.
received grants for clinical research from Bristol-Myers-Squibb, Daiichi-
Sankyo, Sanofi-Aventis, and Servier. J.C. served as an advisor, speaker
and/or, consultant for Actelion Pharmaceuticals, ARYx Therapeutics,
Bristol-Myers-Squibb, Cardiome Pharma, CV Therapeutics, Daiichi-
Sankyo, Menarini Group, Merck, Novartis Pharmaceuticals, Pfizer,
Sanofi-Aventis, Servier, and Xention. He served as a member of the
data and safety monitoring board for Bristol-Myers-Squibb, Novartis
Pharmaceuticals and Servier. He served as an expert witness for
Johnson & Johnson, Sanofi-Aventis and Servier.
P.K. received consulting fees and honoraria from 3 M Medica, MEDA
Pharma, AstraZeneca, Bayer Healthcare, Biosense Webster, Boehringer-
Ingelheim, Daiichi-Sankyo, German Cardiac Society, MEDA Pharma,
Medtronic, Merck, MSD, Otsuka Pharma, Pfizer/BMS, sanofi, Servier, Sie-
mens, TAKEDA, and support for research from 3 M Medica/MEDA Pharma,
Cardiovascular Therapeutics, Medtronic, OMRON, SANOFI, St Jude Med-
ical, German Federal Ministry for Education and Research (BMBF), Fonda-
tion Leducq, German Research Foundation (DFG), and the European
Union (EU).
References
1. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P,
Camm AJ, Kirchhof P. European Heart Rhythm Association Practical Guide on
the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
Europace 2013;15:625–651.
2. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P,
Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants
in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;
34:2094–2106.
3. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J,
Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association
Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients
with non-valvular atrial fibrillation. Europace 2015;17:1467–1507.
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,
Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D,
Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M,
Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A,
Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R,
Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M,
Vardas PE, Widimsky P, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C,
Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M, Gulba DC,
Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ,
Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines
for the management of atrial fibrillation: the Task Force for the Management of Atrial
Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–1420.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G,
Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R,
Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C,
Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A,
Vahanian A, Windecker S, Vardas P, Al-Attar N, Alfieri O, Angelini A,
Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B,
Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Le Heuzey JY, Mavrakis H,
Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van
Gelder IC, Verheugt FW. 2012 focused update of the ESC Guidelines for the man-
agement of atrial fibrillation: An update of the 2010 ESC Guidelines for the man-
agement of atrial fibrillation * Developed with the special contribution of the
European Heart Rhythm Association. Europace 2012;14:1385–1413.
6. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB,
Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG,
Tchou PJ, Tracy CM, Yancy CW, Members AATF. 2014 AHA/ACC/HRS guide-
line for the management of patients with atrial fibrillation: a report of the
American College of Cardiology/American Heart Association Task Force on
practice guidelines and the Heart Rhythm Society. Circulation 2014;130:
e199–e267.
7. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R,
Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB,
Alexander JH. Apixaban compared with warfarin in patients with atrial fibrillation
and valvular heart disease: findings from the ARISTOTLE trial. Circulation 2015;132:
624–632.
8. Ezekowitz MD, Parise H, Nagarakanti R, Noack H, Brueckmann M, Clemens A,
Reilly P, Connolly S, Yusuf S, Wallentin L. Comparison of dabigatran versus warfarin
in patients with atrial fibrillation and valvular heart disease: the RE-LYw trial. J Am
Coll Cardiol 2014;63(12 Suppl.):A325.
9. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR,
Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC,
Nessel CC, Mahaffey KW, Fox KA, Califf RM. Clinical characteristics and outcomes
with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but
underlying native mitral and aortic valve disease participating in the ROCKET AF
trial. Eur Heart J 2014;35:3377–3385.
10. De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reappraisal. Eur
Heart J 2014;35:3328–3335.
11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF,
Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med 2011;365:883–891.









alavasi user on 09 N
ovem
ber 2020
12. Granger C, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, Hylek E,
Ansell JE, Wallentin L. Events after discontinuation of randomized treatment at
the end of the ARISTOTLE trial. Eur Heart J 2012;33(suppl.):685–686 (abstract).
13. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L,
Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical events
after transitioning from apixaban versus warfarin to warfarin at the end of the Apix-
aban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrilla-
tion (ARISTOTLE) trial. Am Heart J 2015;169:25–30.
14. Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, Grip L, Cange AL,
Crompton AE, Murphy SA, Deenadayalu N, Antman EM. Transition of patients
from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48
trial. J Am Coll Cardiol 2014;64:576–584.
15. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S,
Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional man-
agement of novel oral anticoagulants in daily care: results from the prospective
Dresden NOAC registry. Eur Heart J 2014;35:1888–1896.
16. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M,
Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R,
Lip GY, Document Reviewers, Gorenek B, Indik JH, Kirchhof P, Ma CS,
Narasimhan C, Piccini J, Sarkozy A, Shah D, Savelieva I. Antithrombotic manage-
ment in patients undergoing electrophysiological procedures: a European Heart
Rhythm Association (EHRA) position document endorsed by the ESC Working
Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm
Society (APHRS). Europace 2015;17:1197–1214.
17. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS,
Ayala-Paredes F, Coutu B, Leiria TL, Essebag V, for the BRUISE CONTROL Inves-
tigators. Pacemaker or defibrillator surgery without interruption of anticoagula-
tion. N Engl J Med 2013;368:2084–2093.
18. Rowley CP, Bernard ML, Brabham WW, Netzler PC, Sidney DS, Cuoco F,
Sturdivant JL, Leman RB, Wharton JM, Gold MR. Safety of continuous anticoagula-
tion with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol
2013;111:1165–1168.
19. Jennings JM, Robichaux R, McElderry HT, Plumb VJ, Gunter A, Doppalapudi H,
Osorio J, Yamada T, Kay GN. Cardiovascular implantable electronic device im-
plantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
J Cardiovasc Electrophysiol 2013;24:1125–1129.
20. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ,
Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD,
Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P,
Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K,
Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F,
Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C,
Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D.
2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical
Ablation of Atrial Fibrillation: recommendations for patient selection, procedural
techniques, patient management and follow-up, definitions, endpoints, and re-
search trial design. EP Europace 2012;14:528–606.
21. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R,
Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S,
Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G,
Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C,
Schweikert RA, Natale A. periprocedural stroke and bleeding complications in
patients undergoing catheter ablation of atrial fibrillation with different anticoagula-
tion management: results from the role of coumadin in preventing thromboembol-
ism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE)
randomized trial. Circulation 2014;129:2638–2644.
22. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ,
Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De
Chillou C, Davies DW, Fields LE, Natale A, on Behalf of the VENTURE-AF Inves-
tigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for
catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805–1811.
23. Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O. Reversal of
dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex
concentrates and idarucizumab. Thromb Haemost 2015;113:728–740.
24. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R,
Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J,
Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J
Med 2015;373:511–520.
25. Lauw MN, Coppens M, Eikelboom JW. Recent advances in antidotes for direct oral
anticoagulants: their arrival is imminent. Can J Cardiol 2014;30:381–384.
26. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V,
Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edox-
aban. N Engl J Med 2014;371:2141–2142.
27. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A,
Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleeding
following punch biopsy and reversal by a 4-factor prothrombin complex concen-
trate. Circulation 2015;131:82–90.
28. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of
rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized,
placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573–1579.
29. Perlstein I, Wang Z, Song Y, Wang J, Bedford B, Chang M, Pursley J, LaCreta F,
Frost R, Frost C. Reversal of apixaban anticoagulation by 4-factor prothrombin
complex concentrates in healthy subjects. Blood 2014;124:345.
30. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagu-
lant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant
factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;
93(Suppl. 1):148.
31. Dentali F, Marchesi C, Giorgi Pierfranceschi M, Crowther M, Garcia D, Hylek E,
Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin com-
plex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A
meta-analysis. Thromb Haemost 2011;106:429–438.
32. Baudo F, Collins P, Huth-Kuhne A, Levesque H, Marco P, Nemes L, Pellegrini F,
Tengborn L, Knoebl P, EACH2 Registry Contributors. Management of bleeding
in acquired hemophilia A: results from the European Acquired Haemophilia
(EACH2) Registry. Blood 2012;120:39–46.
33. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G,
Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus
warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardi-
oversion. Circulation 2011;123:131–136.
34. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J,
Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M,
Alexander JH, Granger CB, Committees A, ARISTOTLE Committees and Investiga-
tors. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation:
insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63:1082–1087.
35. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ,
Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G,
Committee RAS, ROCKET AF Steering Committee & Investigators. Outcomes
after cardioversion and atrial fibrillation ablation in patients treated with rivaroxa-
ban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998–2006.
36. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M,
Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P,
van Eickels M, Hohnloser SH, on Behalf of the X-VeRT Investigators. Rivaroxaban vs. vita-
min K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346–3355.
37. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG,
Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF,
Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C,
Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Manage-
ment of antithrombotic therapy in atrial fibrillation patients presenting with acute cor-
onary syndrome and/or undergoing percutaneous coronary or valve interventions: a
joint consensus document of the European Society of Cardiology Working Group on
Thrombosis, European Heart Rhythm Association (EHRA), European Association of
Percutaneous Cardiovascular Interventions (EAPCI) and European Association of
Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-
Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155–3179.
38. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M,
Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of anti-
platelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-
Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634–640.
39. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clo-
pidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial
fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (AC-
TIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.
40. Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH,
Lip GY. Intracranial hemorrhage and subsequent ischemic stroke in patients with
atrial fibrillation: a nationwide cohort study. Chest 2015;147:1651–1658.
41. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Re-
starting anticoagulant treatment after intracranial hemorrhage in patients with atrial
fibrillation and the impact on recurrent stroke, mortality, and bleeding: a Nation-
wide Cohort Study. Circulation 2015;132:517–525.
42. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE,
Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD. Low-dose
and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:
a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Col-
laborators. Lancet 1999;353:2179–2184.
43. Heidbuchel H, Vrijens B. Non-vitamin K antagonist oral anticoagulants (NOAC):
considerations on once- vs. twice-daily regimens and their potential impact on
medication adherence. Europace 2015;17:1317–1318.









alavasi user on 09 N
ovem
ber 2020
